Filer Snapshot

Ali Tehrani

CIK 0001761853. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Individual

Total filings

11

Latest filing

16 Jul 2021

Industry

n/a

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: Forms 3/4/5 owner position for ZYME. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Open owner activity Save page

Largest parsed holding

—

Populates from the latest parsed 13F information table.

Open holding

13D/G large stake

—

No recent parsed 13D/G stake row for this CIK.

Browse 13D/G

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it
Source: SEC Forms 3/4/5

4 filed on 16 Jul 2021 for CIK 0001761853.

View source filing
Ownership signals CIK-linked ownership evidence from parsed SEC filings. 1 signal
Parsed SEC ownership signals

Parsed SEC ownership coverage

These bars compare filing-backed value available in each disclosure family. Read them as separate lenses, not as one combined ownership total.

Forms 3/4/5 positions$1.42M

Reporting-owner positions with enough filing detail to estimate value.

Forms 3/4/5 position value

3/4/5
$1.42M

Estimated from parsed Forms 3/4/5 when filings include enough share and price data.

Source: Forms 3/4/5Confidence: Estimated when price data is available

Largest linked holdings

Largest issuer positions linked to this CIK across parsed 13F, 13D/G, and Forms 3/4/5 records.

ZYME
How to read these SEC ownership signals
  • Read each filing family separately: Form 13F, Schedules 13D/G, and Forms 3/4/5 answer different SEC disclosure questions and should not be blended into one ownership total.
  • Use 13F values for visible U.S.-listed equity portfolios, 13D/G rows for large beneficial-owner stakes, and Forms 3/4/5 rows for reporting-owner positions and transactions.
  • Open the linked research path when you need the filing, CIK, issuer, CUSIP, date, or source trail behind a value.
At a glance Names, identifiers, and filing context for this profile. 1 identity field
Business address
1385 West 8 Th Avenue, Suite 540, Vancouver, British Columbia, Canada, V6H3V9

Filer intelligence

What SEC filings say about Ali Tehrani

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Save filer

Quick read

  • Forms 3/4/5 show insider context for ZYME worth $1.42M.

SEC source mix

Counts show available parsed rows, not one combined ownership total.

XML parsed
13F portfolio No rows yet

Quarterly institutional portfolio holdings.

Open
13D/G stakes No rows yet

Beneficial ownership and large-stake disclosures.

Open
Forms 3/4/5 1 rows

Officer, director, and 10% owner holdings or transactions.

Open

Forms 3/4/5 insider context

ZYME

15 Jul 2021 · Chief Executive Officer

$1.42M
Issuer page Owner page

Latest update

What changed recently for Ali Tehrani

Ownership report updated

Latest ownership report period: 15 Jul 2021. Open the source-backed page to inspect the fresh filing or facts context.

Update date

16 Jul 2021

Page type

Ownership filings

Latest period

15 Jul 2021

Ownership context was refreshed from SEC Forms 3/4/5 filed on 16 Jul 2021.

Open ownership filings Browse recent public updates

SEC filing record

CIK 0001761853 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
11
First seen
02 Jan 2019
Latest filing
16 Jul 2021
Entity
Individual

Observed form types

4 3

CIK-linked evidence first

Ali Tehrani SEC filings Ali Tehrani owner filings Open SEC filing index

Latest Filings

Showing the latest 11 of 11 SEC filings for Ali Tehrani.

4 File 001-38068

FORM 4 SUBMISSION

Filing date
16 Jul 2021
Reporting date
15 Jul 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 001-38068

FORM 4 SUBMISSION

Filing date
13 Jul 2021
Reporting date
12 Jul 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 001-38068

FORM 4 SUBMISSION

Filing date
12 Mar 2021
Reporting date
10 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 001-38068

FORM 4 SUBMISSION

Filing date
09 Dec 2020
Reporting date
07 Dec 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 001-38068

FORM 4 SUBMISSION

Filing date
04 Nov 2020
Reporting date
02 Nov 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 001-38068

FORM 4 SUBMISSION

Filing date
13 Apr 2020
Reporting date
13 Apr 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 001-38068

FORM 4 SUBMISSION

Filing date
07 Apr 2020
Reporting date
03 Apr 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 001-38068

FORM 4 SUBMISSION

Filing date
11 Mar 2020
Reporting date
10 Mar 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 001-38068

FORM 4 SUBMISSION

Filing date
29 Mar 2019
Reporting date
29 Mar 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
4 File 001-38068

FORM 4 SUBMISSION

Filing date
10 Jan 2019
Reporting date
08 Jan 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
3 File 001-38068

FORM 3 SUBMISSION

Filing date
02 Jan 2019
Reporting date
01 Jan 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .